trending Market Intelligence /marketintelligence/en/news-insights/trending/5ddqy28r3aj7k7wvwzpasw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Parnell Pharmaceuticals delisting from Nasdaq

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Parnell Pharmaceuticals delisting from Nasdaq

Australia-based Parnell Pharmaceuticals Holdings Ltd. will delist from the Nasdaq, effective Dec. 31.

The company said it believes that there has been an incongruence between the potential realizable value of Parnell's underlying assets and its share price as a Nasdaq-listed company, according to a news release.

The veterinarian pharmaceutical company anticipates its shares to be quoted on the OTC Pink open market following the delisting.